Evidence map›Paper›PMID 24263156›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy.

Jiacheng Ma, Kevin L Farmer, Pan Pan, Michael J Urban, Huiping Zhao, Brian S J Blagg, Rick T Dobrowsky

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Neurobiological Opportunities in Diabetic Polyneuropathy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. Muscarinic Toxin 7 Signals Via CaMolecular neurobiology · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiacheng MaDepartment of Pharmacology and Toxicology (J.M., K.L.F., P.P. M.J.U., R.T.D.) and Department of Medicinal Chemistry (H.Z., B.S.J.B.), The University of Kansas, Lawrence, Kansas.
Kevin L Farmer
Pan Pan
Michael J Urban
Huiping Zhao
Brian S J Blagg
Rick T Dobrowsky
University of Kansas · US

Funding

Chaperone therapeutics for the treatment of DPNR01NS075311 · NINDS · UNIVERSITY OF NOTRE DAME · PI BLAGG, BRIAN S J, DOBROWSKY, RICK T · 2012 to 2020
$2.8M
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`U01CA120458 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI BLAGG, BRIAN S J · 2007 to 2014
$2.6M
HSP90 InhibitorsU01CA109265 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI BLAGG, BRIAN S J · 2006 to 2014
$2.2M
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`R01CA120458 · NCI · UNIVERSITY OF NOTRE DAME · PI BLAGG, BRIAN S J · 2006 to 2019
$1.9M
Caveolin-1 and Altered Neuregulinism in Diabetic NeuropathyR01NS054847 · NINDS · UNIVERSITY OF KANSAS LAWRENCE · PI DOBROWSKY, RICK T · 2008 to 2012
$1.6M
Chaperones in Diabetic Peripheral NeuropathyR01DK095911 · NIDDK · UNIVERSITY OF KANSAS LAWRENCE · PI DOBROWSKY, RICK T · 2013 to 2016
$1.3M
NCI NIH HHS CA109265NCI NIH HHS CA120458NCI NIH HHS R01 CA120458NCI NIH HHS U01 CA109265NCI NIH HHS U01 CA120458NIDDK NIH HHS DK095911NIDDK NIH HHS R01 DK095911NINDS NIH HHS NS054847NINDS NIH HHS NS075311NINDS NIH HHS R01 NS054847NINDS NIH HHS R01 NS075311
6 · The paper itself

Abstract

Impaired neuronal mitochondrial bioenergetics contributes to the pathophysiologic progression of diabetic peripheral neuropathy (DPN) and may be a focal point for disease management. We have demonstrated that modulating heat shock protein (Hsp) 90 and Hsp70 with the small-molecule drug KU-32 ameliorates psychosensory, electrophysiologic, morphologic, and bioenergetic deficits of DPN in animal models of type 1 diabetes. The current study used mouse models of type 1 and type 2 diabetes to determine the relationship of changes in sensory neuron mitochondrial bioenergetics to the onset of and recovery from DPN. The onset of DPN showed a tight temporal correlation with a decrease in mitochondrial bioenergetics in a genetic model of type 2 diabetes. In contrast, sensory hypoalgesia developed 10 weeks before the occurrence of significant declines in sensory neuron mitochondrial bioenergetics in the type 1 model. KU-32 therapy improved mitochondrial bioenergetics in both the type 1 and type 2 models, and this tightly correlated with a decrease in DPN. Mechanistically, improved mitochondrial function following KU-32 therapy required Hsp70, since the drug was ineffective in diabetic Hsp70 knockout mice. Our data indicate that changes in mitochondrial bioenergetics may rapidly contribute to nerve dysfunction in type 2 diabetes, but not type 1 diabetes, and that modulating Hsp70 offers an effective approach toward correcting sensory neuron bioenergetic deficits and DPN in both type 1 and type 2 diabetes.

Indexed as

AnimalsCells, CulturedDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NeuropathiesDose-Response Relationship, DrugFemaleGanglia, SpinalHSP70 Heat-Shock ProteinsHypoglycemic AgentsMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMitochondriaHSP70 Heat-Shock ProteinsHypoglycemic AgentsKU-32 compoundNeuroprotective AgentsNovobiocin

Identifiers

PMID24263156
PMCPMC3912549
OpenAlexW2107449846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.